Research Article
Serum IL-5 and IFN-γ Are Novel Predictive Biomarkers for Anti-PD-1 Treatment in NSCLC and GC Patients
Table 1
The clinicopathological parameters of patients.
| Parameters | NSCLC | Gastric cancer |
| Gender, (%) | Male | 34 (85) | 23 (65.7) | Female | 6 (15) | 12 (34.3) | Age (year) | ⩽60 | 13 (32.5) | 10 (28.5) | >60 | 27 (67.5) | 25 (71.5) | Has smoking history | 32 (80) | 21 (60) | Brain metastasis | 2 | 0 | Eastern Cooperative Oncology Group status (ECOG), (%) | 0 | 7 (17.5) | 2 (5.7) | 1 | 30 (75) | 26 (74.2) | 2 | 3 (7.5) | 7 (20.1) | Adenocarcinoma | 26 (65) | 35 (100) | Squamous cell carcinoma | 14 (35) | 0 | First-line treatment | 18 (45) | 9 (25.7) | Second- and third-line treatment | 22 (55) | 26 (74.2) | Complete remission (CR) | 4 (10) | 2 (5.7) | Partial remission (PR) | 12 (30) | 6 (17.1) | Stable disease (SD) | 13(32.5) | 9 (25.7) | Disease progression (PD) | 9 (22.5) | 18 (51.4) |
|
|